Introduction
The tribbles (Trib) family of pseudokinase genes (Trib1, Trib2, and Trib3) have recently emerged as important regulators of acute leukemia and hematopoietic development. 1 Trib proteins' diverse roles include cell proliferation, survival, motility, and metabolism. 2 There is a strong correlation between dysregulated Trib2 expression and acute myeloid and lymphoid leukemia (AML and ALL). Elevated Trib2 expression associates with a specific subset of AML characterized by dysregulated CCAAT enhancer-binding protein a (C/EBPa) and with T-cell ALL (T-ALL), both linked with NOTCH1 mutations. [3] [4] [5] Mice reconstituted with hematopoietic stem cells (HSCs) retrovirally expressing Trib2 developed AML. The proteasomalmediated degradation and inhibition of C/EBPa was required for the leukemogenic activity of Trib2. [4] [5] [6] Although Trib2 appears to integrate a wide variety of signaling pathways, the molecular understanding of how its expression is controlled in normal and malignant hematopoiesis is limited.
We identified Trib2 as a NOTCH1-regulated transcript in T-ALL cells undergoing growth arrest. As well as NOTCH1, 3 ,5 PITX1 7 and TAL1 8 were also found to up-regulate Trib2 in T-ALL. Both PITX1 and TAL1 are recurrently activated transcription factors in T-ALL and importantly require the expression of Trib2 for leukemic cell growth and survival. 8 In AML cells, MEIS1 was found to bind to the Trib2 promoter, and Trib2 could confer growth-enhancing properties to NUP98-HOXD13/MEIS1-AML cells. 9 Additionally, Trib2 expression is regulated by microRNAs in leukemia cells. 10, 11 It is clear therefore that Trib2 expression is controlled in a cell type-, cell context-, and cell cycle-dependent manner.
The role of Trib2 in cell cycle and cell proliferation is supported by an established role for Drosophila Tribbles (dTRIB) in the cell cycle. dTRIB coordinates cell division during gastrulation by promoting turnover of the cell cycle protein String/CDC25, thereby inhibiting premature mitosis. [12] [13] [14] A further study suggested that dTRIB controls mitosis through inhibition of String and positive regulation of WEE1, as coexpression of WEE1 and Tribbles showed strong synergistic interactions that resulted in severe eye and wing developmental defects. 15 Studies of mammalian Trib2 thus far indicate the genetic interactions of dTRIB and other Drosophila homolog proteins are conserved in the mammalian system. dTRIB promotes the degradation of Slbo, the Drosophila homolog of the C/EBP family of transcription factors, thereby inhibiting Slbo-dependent border cell migration during oogenesis, 16 and inactivation of C/EBPa by Trib2 has been shown in the hematopoietic system to block myeloid cell differentiation. 4 Likewise, dTRIB has a positive genetic interaction with N (the Drosophila homolog of NOTCH), 17 and this is conserved in mammals as Trib2 was found to be a direct transcriptional target gene of NOTCH1. 5 The transcription factor C/EBPa is a critical regulator of myeloid cell proliferation and differentiation. C/EBPa is frequently dysregulated in AML as a result of mutation, posttranscriptional modifications, posttranslational inhibition, epigenetic regulation, and proteasomal degradation. It is also an important tumor suppressor as it regulates a variety of cell cycle proteins. 18 C/EBPa mRNA encodes for 2 major protein isoforms, C/EBPa-p42 and C/EBPa-p30, produced by alternative translational start codons. We have previously shown that Trib2 degrades C/EBPa-p42 and blocks differentiation, with an increase in the C/EBPa-p30 oncogenic protein. In addition to Trib1-and Trib2-mediated dysregulation, 19 the normal protein expression ratio of p42:p30 is skewed in AML as a result of gene mutation. 20 Importantly, the p30 isoform lacks a transactivation domain in the N terminus important for antimitotic activity. This N-terminal domain is crucial for growth arrest by E2F1-mediated regulation of c-Myc expression, and C/EBPa-p42 interferes with E2F1 transactivation of the c-Myc promoter. [21] [22] [23] E2F1 is a master regulator of cell cycle progression. C/EBPa inhibition of E2F1 additionally occurs via protein-protein interaction in non-DNA-binding residues in the C-terminal region of C/EBPa present in both p30 and p42. 22 Mutation of the C-terminal residues of C/EBPa that interact with E2F1 (BRM2) leads to a transplantable disorder of the myeloid lineage with expansion of myeloid progenitors. This revealed a role of C/EBPamediated E2F1 repression in controlling the proliferation of myeloid progenitors. 24 Importantly, however, null mutations in CEBPA do not occur in AML, and C/EBPa-deficient HSCs do not lead to AML, 25, 26 demonstrating that C/EBPa is required for AML to develop.
The E2F family of cell cycle regulators are generally classed as transcriptional activators (E2F1, E2F2, E2F3a, and E2F3b) or repressors (E2F4, E2F5, E2F6, E2F7, and E2F8), but this simple classification lacks in vivo validation.
27 E2F1-3-deficient hematopoietic cells have a defect in myeloid cell differentiation, with an accumulation of granulocyte/macrophage progenitor (GMP) cells and a decrease in CD11b 1 myeloid cells in the bone marrow. E2F1-3s are thus required for cell survival and proliferation at distinct stages during myeloid differentiation. 28 AML with CEBPA mutations has increased E2F3 and decreased miR-34a levels, which C/EBPa normally regulates in myeloid cells. 29 Additional studies support a molecular network involving miR-223, C/EBPa, and E2F1 as major components of the granulocyte differentiation program, which is deregulated in AML. 30 We show here that E2F1, as well as E2F2 and E2F3, is a potent inducer of Trib2 expression and that E2F1 cooperates with C/EBPap30 to further activate the Trib2 promoter in preleukemic cells, resulting in elevated Trib2 expression. Conversely, in normal myeloid progenitor cells, C/EBPa-p42 is found bound to the Trib2 promoter and inhibits E2F1-mediated activation of Trib2. We demonstrate that inhibition of the E2F1-Trib2 regulatory loop results in cell cycle arrest and inhibition of leukemic cell proliferation. In addition, we show that targeted inhibition of this pathway does not affect the growth and survival of normal hematopoietic cells. Our work demonstrates that Trib2 expression is regulated by E2F1 in vivo, and C/EBPa-p30 cooperates with E2F1 to activate Trib2 expression, thus preventing C/EBPa-p42-mediated E2F1 repression, ultimately contributing to the uncontrolled proliferation and cell cycle progression seen in AML.
Methods
Trib2-dependent reporter gene assay 3T3 cells were transfected with luciferase constructs alone or in combination with other expression plasmids and luminescence readings taken (see supplemental Methods on the Blood Web site for details).
Electromobility shift assay
Nonradiolabeled electromobility shift assays (EMSAs) using the LightShift Chemiluminescent EMSA Kit (Thermo Scientic) were performed on nuclear extracts prepared from cells using wild-type (WT) and mutant probes. Specificity was assessed by cold competition (see supplemental Methods for details).
Chromatin immunoprecipitation
Cells were fixed and resuspended in lysis buffer. Isolated nuclei were resuspended in shearing buffer (Active Motif) and sonicated on ice. Protein/ DNA complexes were immunoprecipitated with the indicated antibody, and DNA was eluted as per the manufacturer's instructions (Active Motif) and column purified (QIAquick Purification Kit; Qiagen). Eluted DNA was subjected to polymerase chain reaction (PCR) using promoter-specific primer sets (see supplemental Methods for details).
Mice

Trib2
2/2 (B6;129S5-Trib2tm1Lex) mice, backcrossed onto C57B6, were bred and housed in the University of Glasgow. Cebpa transgenic mice 31 were bred and housed in the University of Copenhagen (see supplemental Methods for details). All mouse work was performed according to national and international guidelines and approved by the local United Kingdom and Danish Animal Ethical Committees.
Dataset analysis
Gene expression values for Trib2 vs E2F1 (GSE14468 and GSE1159) were plotted, and the line of best fit was calculated using linear regression (see supplemental Methods for details).
Cell cycle and proliferation analysis
Cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) for 10 minutes and treated. Drug-treated cells were also fixed and stained with Propidium Iodide (PI)/RNase staining buffer (BD Pharmingen) (see supplemental Methods for details). 
Patient AML samples
Blood samples from newly diagnosed AML patients and normal peripheral blood samples were collected following protocol approved by the Ethics Review Board and with informed consent. Mononuclear cells were isolated using Histopaque (Sigma-Aldrich) according to the manufacturer's instructions. This study was conducted in accordance with the Declaration of Helsinki.
See supplemental Methods for all other details.
Results
To investigate how Trib2 expression is regulated, we cloned 2 promoter regions of Trib2 into the pGL3 luciferase reporter: (1) 500 bp upstream from the transcriptional start site (2500 to 11 bp) and (2) including the entire 59 untranslated region (UTR) and upstream region (22.6 kb to 11 bp). The promoter activity was assessed in 293T cells, 3T3 cells, and RAW264.7 cells. Increased Trib2 promoter activity was seen in 293T and 3T3 cell lines but not the RAW cell line with the 2.6-kb promoter construct compared with the 500-bp promoter ( Figure 1A ). We analyzed the promoter region of Trib2 using TESS bioinformatic software and found 3 putative consensus E2F binding sites within the Trib2 promoter. Two sites were located within the 1.3-kb 59UTR (site B at 2943 bp and site C at 2811 bp), and 1 site was further upstream (site A at 22.1 kb; Figure 1B ). We assessed the activation of the Trib2 promoter by cotransfection with E2F1 in 3T3 and K562 myeloid cells. E2F1 expression significantly increased the promoter activity of the 2.6-kb construct in both cell types ( Figure 1C ,E). We performed the promoter activity assay using an E2F1 DNA binding mutant (E132 mutant) and showed that, in the absence of direct DNA binding, E2F1 is unable to activate the Trib2 promoter in both 3T3 and K562 cells ( Figure 1D -E). Together these data suggest that Trib2 is a target of E2F1.
To identify the role of the predicted E2F1 sites in the Trib2 promoter regions, we constructed a number of deletion and mutagenized promoter constructs in the luciferase reporter (schematic representation in Figure 2A -B, upper panels, respectively). We tested the promoter activity in the presence and absence of exogenous E2F1 expression. Activation of the 500-bp promoter region can be modestly increased by expression of E2F1 (as seen in Figures 1C and 2A) , despite the lack of a consensus E2F1 binding site in that region. This indicates a potential nonconsensus E2F1 binding site or E2F1-mediated activation via protein-protein interactions. Using deletion constructs containing only site B (2963-bp construct with site C mutated) or only site C (2927-bp construct; Figure 2A , upper left) revealed that in the absence of site A and site B or C, E2F1 is able to further activate the Trib2 promoter but is unable to restore complete activation as seen in the full-length promoter construct (Figure 2A, lower) . We then performed site-directed mutagenesis of sites A, B, and C in the 2.6-kb promoter construct. Luciferase activity assay revealed that mutation of site A or C alone did not abrogate or inhibit E2F1-induced promoter activity, whereas mutation of B alone or both , and RAW264.7 cells were cotransfected with empty pGL3 Basic or 500-bp Trib2 promoter or 2.6-kb Trib2 promoter constructs and luciferase activity was measured. (B) Schematic presentation of the Trib2 promoter region 2.6 kb upstream from the transcriptional start site and the location of 3 putative E2F binding sites. (C) 3T3 cells were cotransfected with E2F1 or pcDNA empty expression vector and Trib2 luciferase reporter plasmids (pGL3 control, 500-bp, or 2.6-kb promoter region) and luciferase activity was measured. (D) 3T3 cells were cotransfected with E2F1 or E2F1 E132 DNA binding deficient mutant expression vectors and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter) and luciferase activity was measured. Data presented are mean 6 standard deviation (SD) of duplicate cultures and representative of 3 independent experiments. **P , .005 and ***P , .001 using an unpaired Student t test. (E) K562 cells were cotransfected with E2F1 or E2F1 E132 DNA binding deficient mutant expression vectors or empty control vector and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter) and luciferase activity was measured. Data presented are mean 6 SD and representative of 3 independent experiments. **P , .005 using an unpaired Student t test. 6-kb and deletion mutant Trib2 promoter constructs with the indicated E2F1 binding sites. 3T3 cells were (lower left) transfected with Trib2 luciferase reporter plasmids (pGL3 control, 2.6-kb, 500-bp, 927-bp, or 963-bp promoter region) and (lower right) cotransfected with E2F1 or pcDNA empty expression vector, and luciferase activity was measured. (B) (Upper) Schematic presentation of full-length 2.6 kb with site-directed mutations of the 3 putative E2F1 binding sites. 3T3 cells were (lower left) transfected with Trib2 luciferase reporter plasmids (pGL3 control, 2.6-kb, MutA, MutB, MutC, or double mutant DM) and (lower right) cotransfected with E2F1 or pcDNA empty expression vector, and luciferase activity was measured. Data presented are mean 6 SD of duplicate cultures and representative of 3 independent experiments. *P , .05, **P , .005, and ***P , .001. (C) Nuclear extracts prepared from K562 cells transfected with pcDNA3 empty or E2F1 were assayed for E2F1 binding for sites A, B, and C by EMSA. Arrow indicates E2F1 binding. FP, free probe; comp, cold competition; MT, mutant type. (D) 3T3 cells were cotransfected with E2F1 WT or E2F1 E132 DNA binding deficient mutant or empty expression vector and Trib2 luciferase reporter constructs (pGL3 control, 2.6-kb, 500-bp, or DM promoter region), and luciferase activity was measured. Data presented are mean 6 SD of duplicate cultures and representative of 2 independent experiments. **P , .005 and ***P , .001 using an unpaired Student t test. (E) K562 cells were cotransfected with E2F1 WT or E2F1 E132 DNA binding deficient mutant or empty expression vector and Trib2 luciferase reporter constructs (pGL3 control, 2.6-kb, 500-bp, or DM promoter region), and luciferase activity was measured. Data presented are mean 6 SD and representative of 2 independent experiments. ***P , .001 using an unpaired Student t test.
sites B and C together reduced Trib2 promoter activity ( Figure 2B , lower). EMSA analysis showed that, on transfection of K562 cells with E2F1, there was an increase in binding to the WT probes for the E2F1-specific sites A, B, and C and a lack of E2F1-inducible binding to 3 distinct mutant probes for sites A, B and C ( Figure 2C ). Mutation of B and C together significantly reduced Trib2 promoter activity in both 3T3 ( Figure 2D ) and K562 cells ( Figure 2E ) but not to as great an extent as the 500-bp promoter (lacks sites A, B, and C). Together, these data reveal that E2F1 binds at sites A, B, and C in the Trib2 promoter in fibroblasts and myeloid cells.
We next tested whether this was specific to E2F family members. Luciferase assays in 3T3 cells using the full-length 2.6-kb Trib2 promoter construct revealed that E2F1, E2F2, E2F3, and E2F4 activated the Trib2 promoter, whereas E2F5 was unable to induce Trib2 promoter activity ( Figure 3A) . To test the ability of these E2F family members to bind to Trib2 promoter in a myeloid leukemia cell, we performed chromatin immunoprecipitation (ChIP) analysis using antibodies for endogenous E2F1, E2F2, E2F3, E2F4, and E2F5 in K562 cells (express high levels of Trib2 protein; Figure 7E ). In comparison with the IgG-negative control, there was enrichment Figure 3 . Other E2F family members can bind and activate Trib2 promoter. (A) 3T3 cells were cotransfected with E2F1, E2F2, E2F3, E2F4, E2F5, or pcDNA empty expression vector and Trib2 luciferase reporter plasmids (pGL3 basic control or 2.6-kb promoter region), and luciferase activity was measured. Data presented are mean 6 SD of duplicate cultures and representative of 3 independent experiments. *P , .05 and ***P , .001. (B) K562 cells were chromatin immunoprecipitated using anti-E2F1, anti-E2F2, anti-E2F3, anti-E2F4, anti-E2F5, antiacetylated histone 4 (Ac-His4), or normal IgG control antibodies. PCR was performed using primers directed against the E2F binding region containing sites B and C and using primers against a 25-kb region as a negative control. Graphs represent fold enrichment of DNA compared with the IgG control and are representative of 3 independent experiments, and error bars denote 6 SD of each sample. *P , .05, **P , .005, and ***P , .001.
, and E2F3 on the Trib2 promoter region containing sites B and C, but not at a 25-kb Trib2 promoter region used as a negative control ( Figure 3B ). The Trib2 promoter region was shown to be transcriptionally active as demonstrated by the presence of acetylated histone 4. There was no significant enrichment of E2F4 or E2F5 on the Trib2 promoter. These data show that E2F1 CD11b 1 myeloid cells 28 revealed a 4.6-fold reduction in Trib2. We also identified putative C/EBPa binding sites in the Trib2 promoter using the TESS bioinformatics analysis tool. Indeed E2F1 binding sites B and C surround a region of the Trib2 promoter that contains a high confidence C/EBP binding site (2900 bp) ( Figure 5A ). C/EBPa-mediated inhibition of E2F1 is pivotal for granulopoiesis. As our previous work has shown that Trib2 degraded C/EBPa-p42 leaving increased expression of the oncogenic C/EBPa-p30 form in AML, we tested whether there was an E2F1-C/EBPa feedback loop regulating Trib2 expression. EMSA revealed that both C/EBPa-p42 and -p30 bind to this region at 2900 bp using a C/EBPa binding site-specific probe ( Figure 5B ). Trib2 promoter assays showed a dose-dependent decrease in activity following cotransfection of increasing doses of C/EBPa-p42 compared with E2F1 alone (Figure 5C, left) . Significantly, cotransfection of E2F1 and C/EBPa-p30 resulted in a dose-dependent increase in E2F1-induced Trib2 promoter activity ( Figure 5C, right) . These data show that the E2F1 regulation of Trib2 can be modulated by the presence of C/EBPa-p42 and C/EBPa-p30. Importantly, Trib2 mRNA expression decreased in myeloid K562 cells on C/EBPap42 expression, and reciprocally, Trib2 expression increased on C/EBPa-p30 expression ( Figure 5D ). This was not due to an increase in E2F protein expression by C/EBPa-p30 (supplemental Figure 1) . This regulation was seen in K562 nuclear extracts at the DNA binding sites, as EMSA analysis showed that C/EBPa-p42 and -p30 modulated the binding of E2F1 to the Trib2 promoter at site B only ( Figure 5E ). The slower-migrating protein complex induced by C/EBPa-p30 contained both E2F1 and C/EBPa-p30 as seen by the disappearance of this complex in a supershift assay, indicating that these proteins are components of this complex ( Figure 5F ). Additionally, the E2F1-induced Trib2 promoter activity in K562 cells was modulated by C/EBPa-p42 and -p30 expression ( Figure 5G ). To investigate the physiological binding of C/EBPa to the Trib2 promoter in the myeloid lineage, we performed ChIP analysis for C/EBPa in normal murine GMPs at 2900 bp. We detected C/EBPa bound to the Trib2 promoter in the region spanning the identified E2F1 binding sites B and C ( Figure 5H ) revealing that in normal GMPs, C/EBPa is recruited onto the Trib2 promoter. This is consistent with the ability of C/EBPa-p42 to inhibit E2F1 in normal myelopoiesis. Interestingly, real-time quantitative PCR analysis of normal WT GMPs compared with GMPs isolated from preleukemic mutant C/EBPa knockin mice that retain p30 expression but have lost p42 expression (Lp30, 2/p30) reveals a significant increase in Trib2 expression in the mutant GMPs ( Figure 5I ). Therefore, in the presence of C/EBPa-p30 in the preleukemic GMP population, Trib2 mRNA expression is increased. Together, these data reveal that C/EBPa localizes to the Trib2 promoter in GMP progenitor cells, and the balance of C/EBPa-p42 and C/EBPa-p30 modulates the ability of E2F1 to activate Trib2 expression in normal and preleukemic myeloid cells.
To target the E2F1 pathway and determine the effect on Trib2 and the leukemic cell, we used known cyclin-dependent kinase inhibitors (CDKis), flavopiridol (a pan CDK inhibitor), 32 pentoxifylline (PTX, a nonspecific phosphodiesterase inhibitor), and dibutyryl cAMP (a cAMP analog). 33 We treated U937 cells (AML cells that express high levels of Trib2 protein; Figure 7E ) with escalating doses of flavopiridol and PTX and assessed cell death ( Figure 6A ). Both flavopiridol (IC 50 of 94 nM) and PTX (IC 50 of 4 mM) were cytotoxic to U937, whereas up to 4 mM dibutyryl cAMP was not cytotoxic. At a lower-dose (2 mM PTX, 4 mM dibutyryl cAMP, and 62.5 nM flavopiridol) treatment at 24 hours, U937 cells underwent G1 cell cycle arrest without increased apoptosis (sub-G1 DNA content) as assessed by propidium iodide staining ( Figure 6B ) and had reduced proliferation as assessed by CFSE staining at 96 hours ( Figure 6C ). Using low drug doses that inhibit cell proliferation but have minimal cytotoxicity and apotosis, we assessed the effect on cell cycle proteins E2F1 and Trib2. Western blot analysis determined that PTX, dibutyryl cAMP, and flavopiridol led to a reduction in Cdk6, Cdk2, phospho-RB (phosphorylated-retinoblastoma), E2F1, and Trib2 with 24-hour treatment ( Figure 6D ). Importantly, global protein expression of RB is not decreased, and C/EBPa levels remain unchanged, if not slightly increased at the lower concentrations when cell cycle arrest occurred. These results show that the inhibition of CDKs results in cell cycle arrest and reduced proliferation, inhibition of E2F1, and a decrease in Trib2. To determine the effect in normal cells, we treated WT and Trib2 knockout (KO; Trib2 (Figure 6E-F) . No cytotoxic effect was seen in colony-forming assays of untreated and treated HSCs from WT and Trib2 2/2 animals ( Figure 6G ). These data show that there is limited cell toxicity of targeting this pathway using these drugs in normal cells or cells that lack Trib2 expression. To prove that inhibition of Trib2 expression plays a role in leukemic cell proliferation, we used lentiviral technology to knockdown Trib2 expression in AML cells ( Figure 7A ; supplemental Figure 2 ). Trib2 knockdown inhibited the growth of AML cells ( Figure 7B ), induced apopotosis and decreased cell viability ( Figure 7C) , and induced G1 cell cycle arrest ( Figure 7D ), indicating that Trib2 expression is required for the survival and proliferation of AML cells. Therefore, to assess the prevalence of high Trib2 expression in AML, we analyzed primary AML patient samples by mRNA and western blot analysis and compared the levels to normal peripheral blood samples (N1-6), normal lymphoblast cell lines (CV1665 and CV1939), and myeloid leukemic cell lines (K562, U937, ML-1, Kasumi, and SB1690CB). We detected high Trib2 expression in AML patient samples compared with normal controls (Figure 7E ). High E2F1 expression correlated with high Trib2 protein expression ( Figure 7E ). AML patient datasets were investigated for a correlative For
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relationship between elevated Trib2 expression and E2F1 expression. Using 2 previously published AML patient microarray datasets, 34, 35 we found a significant positive correlation between E2F1 and the high Trib2-expressing patient samples ( Figure 7F) . As positive controls, we determined that there was a significant positive correlation between Trib2 and NOTCH1 and a significant negative correlation (C) 3T3 cells were cotransfected with empty control, E2F1 alone, or in combination with increasing amount of (left) C/EBPa-p42 or (right) C/EBPa-p30 and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter), and luciferase activity was measured. Data presented are mean 6 SD of duplicate cultures and representative of 2 independent experiments. *P , .05 and **P , .005. (D) K562-C/EBPa-p42-ER and K562-C/EBPa-p30-ER cells induced with b-estradiol or vehicle control for 24 hours were measured for Trib2 mRNA expression by real-time PCR analyses. Data are presented relative to vehicle control and representative of 2 independent experiments. Error bars denote 6SD of each sample measured in triplicate. **P , .005 and ***P , .001. (E) Nuclear extracts prepared from (upper) K562-C/EBPa-p42-ER and (lower) K562-C/EBPa-p30-ER cells transfected with E2F1 and induced with b-estradiol or vehicle control for 24 hours were assayed for E2F1 binding for WT sites B and C by EMSA. FP, free probe. (F) Supershift EMSA assay was performed in nuclear extracts prepared from K562-C/EBPa-p30-ER cells transfected with E2F1 and induced with b-estradiol or vehicle control for 24 hours using antibody specific for E2F1 or C/EBPa. Oligonucleotide for WT site B was used as a probe. FP, free probe. (G) K562 cells were cotransfected with empty control, E2F1 alone, or E2F1 in combination with C/EBPa-p42 or C/EBPa-p30 and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter region), and luciferase activity was measured. Data presented are mean 6 SD and representative of 2 independent experiments. ***P , .001 using an unpaired Student t test. (H) Normal murine GMP cells were chromatin immunoprecipitated using anti-C/EBPa or normal IgG control antibodies. PCR was performed using primers against the region indicated in A. Error bars denote 6SD of each sample measured in triplicate. ***P , .001. (I) Real-time PCR analysis of Trib2 mRNA levels in WT ( For personal use only. on April 21, 2017 . by guest www.bloodjournal.org From between Trib2 and C/EBPa (data not shown). Therefore, these data strongly support the role of E2F1-regulated Trib2 expression in AML and its function in the dysregulation of myeloid cell proliferation.
Our data support the finding that the perturbation of C/EBPa by Trib2 functions in a positive feedback loop to enhance E2F1-mediated Trib2 expression in AML. 
Discussion
Trib2 expression may be differentially regulated depending on the cell type (myeloid or lymphoid, immature or mature), cell context (normal or malignant), and the cell cycle (quiescent or self-renewing or proliferating). Here we described the regulation of Trib2 in normal myeloid and leukemic cells via an E2F1 and C/EBPa feedback mechanism. We demonstrated a correlation between the expression levels of E2F1 and Trib2 in AML cells and showed that E2F1 is recruited to the Trib2 promoter, activating Trib2 expression. E2F1-regulated Trib2 activation was negatively and positively modulated via C/EBPa-p42 and C/EBPa-p30 expression, respectively. We demonstrated the recruitment of C/EBPa-p42 to the Trib2 promoter in normal myeloid cells and the elevation of Trib2 expression in C/EBPa-p30 expressing preleukemic myeloid cells. Our results reveal a positive feedback loop for E2F1, Trib2, and C/EBPa-p30 in AML. Our data suggest that the regulation of Trib2 expression in AML cells is pivotal for AML cell proliferation and survival. The identification of E2F direct gene targets via consensus and nonconsensus binding sites has been globally assessed using ChIP technologies. 36 Indeed the recruitment of E2F1 to promoters does not always require DNA binding, as other transcription factors have been shown to recruit E2F1, such as nuclear factor-kB, Myc, and C/EBPa. 27 C/EBPa-p30 has been shown to recruit E2F1 to the promoter of PIN1, and increased PIN1 expression was proposed to contribute to the differentiation block in AML. 37 We showed and validated the presence of E2F1 binding sites in the Trib2 promoter. Using site-directed and deletional mutagenesis and EMSA analysis, we conclude that E2F1 binds directly to the Trib2 promoter and is modulated by C/EBPa specifically at site B at 2943 bp. We demonstrate the recruitment of C/EBPa to this region in normal GMP cells. Using a ChIP assay, we were unable to distinguish between C/EBPap42 and C/EBPa-p30 binding to the Trib2 promoter in normal or preleukemic cells. It has been suggested that C/EBPa-p30 has independent functions of C/EBPa-p42 and that it can target and modulate a unique set of genes in addition to its role as a dominant negative of C/EBPa-p42. 38, 39 Given that we have shown that C/EBPa-p30 preleukemic GMP cells have elevated Trib2 expression above that present in normal GMPs, these data support the positive feedback loop that we propose between E2F1, C/EBPa, and Trib2.
The central mechanisms identified for the negative regulation of cell proliferation by C/EBPa are repression of E2F, 22 interference with Cdk2 and Cdk4 function, 40 and p21 stabilization (a Cdk inhibitor). 41 Flavopiridol is a small molecule cyclin-dependent kinase inhibitor that induces cell cycle arrest, apoptosis, and clinical responses in AML patients. Following the inhibition of Cdks, phosphorylation of RB is inhibited, and E2F is released and drives cell cycle arrest and apoptosis. Studies have shown that flavopiridol induces apoptosis in leukemic blasts from patients with poor-risk AML or ALL 42 and represses E2F1 expression in leukemic blasts from patients with refractory AML. 43 PTX has been shown to induce cell cycle arrest and apoptosis of AML and ALL cells 44, 45 and has been used in combination therapy for patients with myelodysplastic syndromes and AML. 46, 47 Elevated cAMP, as a result of PTX and dibutyryl cAMP treatment, has been shown to target CDK and E2F1 in leukemic cells, leading to cell cycle arrest, 33 apoptosis, 48 and leukemic cell differentiation. 49 Notwithstanding, these drugs also target other pathways, for instance, nuclear factor-kB and antiapoptotic proteins. 44 Therefore, the inhibition of CDK has been shown to induce a number of effects in different subtypes of AML, which all prove to be detrimental to the leukemic cell (differentiation, cell cycle arrest, and apoptosis). The inhibition of CDK activity in high Trib2-expressing AML cells resulted in the arrest of cells in G1 phase of the cell cycle and a subsequent decrease in cell in S phase. Using concentrations of drug that induced minimal apoptosis and a block in proliferation, there was a decrease in E2F1 expression and a subsequent decrease in Trib2 expression, and these effects ultimately led to apoptotic cell death (sub-G1 increase) of the AML cell. The fact that we did not observe any proliferative defect following treatment in nonleukemic WT and Trib2-deficient BM cells corroborates the role of Trib2 in the control of leukemic cell proliferation.
Here we identify a positive regulatory loop controlled by E2F1 that contributes to the aberrant expression of Trib2 in AML cells. Our findings provide a novel link between oncogenic Trib2 function and AML cell proliferation. Whether E2F-mediated regulation of Trib2 occurs also in ALL remains to be investigated and of great interest.
